CN109890418B - 抗cd19抗体与bcl-2抑制剂的组合及其用途 - Google Patents

抗cd19抗体与bcl-2抑制剂的组合及其用途 Download PDF

Info

Publication number
CN109890418B
CN109890418B CN201780067047.1A CN201780067047A CN109890418B CN 109890418 B CN109890418 B CN 109890418B CN 201780067047 A CN201780067047 A CN 201780067047A CN 109890418 B CN109890418 B CN 109890418B
Authority
CN
China
Prior art keywords
ser
leu
val
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780067047.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN109890418A (zh
Inventor
J·恩德尔
K·帕特普洛斯
P·凯莱门
R·博克斯哈默
M·吕克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG filed Critical Morphosys AG
Priority to CN202410183851.8A priority Critical patent/CN118045175A/zh
Publication of CN109890418A publication Critical patent/CN109890418A/zh
Application granted granted Critical
Publication of CN109890418B publication Critical patent/CN109890418B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780067047.1A 2016-10-28 2017-10-27 抗cd19抗体与bcl-2抑制剂的组合及其用途 Active CN109890418B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410183851.8A CN118045175A (zh) 2016-10-28 2017-10-27 抗cd19抗体与bcl-2抑制剂的组合及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16196184 2016-10-28
EP16196184.2 2016-10-28
PCT/EP2017/077654 WO2018078123A1 (en) 2016-10-28 2017-10-27 Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410183851.8A Division CN118045175A (zh) 2016-10-28 2017-10-27 抗cd19抗体与bcl-2抑制剂的组合及其用途

Publications (2)

Publication Number Publication Date
CN109890418A CN109890418A (zh) 2019-06-14
CN109890418B true CN109890418B (zh) 2024-03-08

Family

ID=57218739

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410183851.8A Pending CN118045175A (zh) 2016-10-28 2017-10-27 抗cd19抗体与bcl-2抑制剂的组合及其用途
CN201780067047.1A Active CN109890418B (zh) 2016-10-28 2017-10-27 抗cd19抗体与bcl-2抑制剂的组合及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202410183851.8A Pending CN118045175A (zh) 2016-10-28 2017-10-27 抗cd19抗体与bcl-2抑制剂的组合及其用途

Country Status (26)

Country Link
US (1) US12358983B2 (enExample)
EP (2) EP3532098B1 (enExample)
JP (3) JP7094950B2 (enExample)
KR (2) KR20230028571A (enExample)
CN (2) CN118045175A (enExample)
AU (2) AU2017348624B2 (enExample)
BR (1) BR112019008244A2 (enExample)
CA (1) CA3037246A1 (enExample)
CY (1) CY1124648T1 (enExample)
DK (1) DK3532098T3 (enExample)
ES (1) ES2871574T3 (enExample)
HR (1) HRP20210838T1 (enExample)
HU (1) HUE054496T2 (enExample)
IL (3) IL320372A (enExample)
LT (1) LT3532098T (enExample)
MX (2) MX2019004942A (enExample)
NZ (1) NZ751414A (enExample)
PL (1) PL3532098T3 (enExample)
PT (1) PT3532098T (enExample)
RS (1) RS62036B1 (enExample)
RU (1) RU2756405C2 (enExample)
SG (1) SG10202104036QA (enExample)
SI (1) SI3532098T1 (enExample)
SM (1) SMT202100347T1 (enExample)
WO (1) WO2018078123A1 (enExample)
ZA (1) ZA201903302B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3954388A1 (en) 2015-08-21 2022-02-16 MorphoSys AG Combinations and uses thereof
IL320372A (en) 2016-10-28 2025-06-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof
LT3630177T (lt) 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
MX2021001908A (es) * 2018-08-31 2021-08-19 Adc Therapeutics Sa Terapia de combinacion.
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR20220104176A (ko) * 2019-10-31 2022-07-26 모르포시스 아게 순차적 항-cd19 요법
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
CN103732252A (zh) * 2011-08-16 2014-04-16 莫佛塞斯公司 使用抗cd-19抗体和氮芥的联合治疗

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
KR20040023565A (ko) 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
KR20080032097A (ko) 2005-06-20 2008-04-14 메다렉스, 인코포레이티드 씨디19 항체 및 그의 용도
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
HRP20140331T1 (hr) 2006-08-14 2014-05-09 Xencor, Inc. Optimizirana antitijela usmjerena na cd19
EP2054335B1 (en) 2006-08-15 2012-04-04 Hydralift Amclyde, Inc. Direct acting single sheave active/passiv heave compensator
MX2009002414A (es) 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP3392273A1 (en) * 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
US20100128586A1 (en) 2008-11-25 2010-05-27 Mediatek Inc. Method and apparatus for accessing data from disc with linking area
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EA031737B1 (ru) 2010-06-03 2019-02-28 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
US8549399B2 (en) 2011-01-18 2013-10-01 Apple Inc. Identifying a selection of content in a structured document
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
RU2646758C2 (ru) * 2013-12-05 2018-03-07 Ф. Хоффманн-Ля Рош Аг Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
ES2818110T3 (es) * 2014-02-28 2021-04-09 Merck Sharp & Dohme Tratamiento del cáncer con una combinación que comprende dinaciclib
PL3888674T3 (pl) * 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
EP3157553A4 (en) 2014-06-16 2018-02-28 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
IL293714A (en) 2014-10-20 2022-08-01 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
SG11201705476WA (en) 2015-02-12 2017-09-28 Seattle Genetics Inc Combination therapy using a cd19-adc and vincristine
WO2016189014A1 (en) 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HRP20191585T1 (hr) 2015-05-26 2019-11-29 Hoffmann La Roche Kombinirana terapija protutijela anti cd20 s inhibitorima bcl-2 i mdm2
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
EP3954388A1 (en) 2015-08-21 2022-02-16 MorphoSys AG Combinations and uses thereof
HRP20210938T1 (hr) 2016-05-30 2021-09-03 Morphosys Ag Postupci za prognozu terapijske dobrobiti od anti-cd19 terapije kod pacijenata
EP3909985A1 (en) 2016-06-27 2021-11-17 MorphoSys AG Anti-cd19 antibody formulations
IL320372A (en) 2016-10-28 2025-06-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof
LT3630177T (lt) 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
SG11202111343TA (en) 2019-05-03 2021-11-29 Morphosys Ag Anti-cd19 therapy in patients having a limited number of nk cells
PH12022551008A1 (en) 2019-10-31 2023-03-20 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
KR20220104176A (ko) 2019-10-31 2022-07-26 모르포시스 아게 순차적 항-cd19 요법
AU2020372646A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells
WO2021259902A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
CA3204063A1 (en) 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
JP2025500411A (ja) 2021-12-22 2025-01-09 インサイト・コーポレイション 抗ｃｄ１９抗体療法のための治療パラダイム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703027A (zh) * 2011-08-16 2014-04-02 莫佛塞斯公司 使用抗cd-19抗体和嘌呤类似物的联合治疗
CN103732252A (zh) * 2011-08-16 2014-04-16 莫佛塞斯公司 使用抗cd-19抗体和氮芥的联合治疗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia;Tadeusz Robak;《Seminars in Oncology》;20160430;第43卷(第2期);第280-290页 *
Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study;Shuo Ma;《Blood》;20151203;第126卷(第3期);第1-4页 *

Also Published As

Publication number Publication date
JP2019533682A (ja) 2019-11-21
CA3037246A1 (en) 2018-05-03
JP7094950B2 (ja) 2022-07-04
RU2019113370A3 (enExample) 2021-03-01
EP3532098A1 (en) 2019-09-04
ES2871574T3 (es) 2021-10-29
AU2017348624A1 (en) 2019-03-28
RS62036B1 (sr) 2021-07-30
JP2022137089A (ja) 2022-09-21
US12358983B2 (en) 2025-07-15
JP2024167208A (ja) 2024-12-03
ZA201903302B (en) 2021-04-28
HRP20210838T1 (hr) 2021-08-06
NZ751414A (en) 2025-10-31
IL301786B2 (en) 2025-09-01
SI3532098T1 (sl) 2021-12-31
IL266216A (en) 2019-06-30
IL266216B1 (en) 2023-05-01
IL301786A (en) 2023-05-01
HUE054496T2 (hu) 2021-09-28
RU2756405C2 (ru) 2021-09-30
PT3532098T (pt) 2021-06-17
RU2019113370A (ru) 2020-11-30
US20190241656A1 (en) 2019-08-08
AU2024287178A1 (en) 2025-01-23
IL266216B2 (en) 2023-09-01
AU2017348624B2 (en) 2024-09-26
WO2018078123A1 (en) 2018-05-03
MX2022016270A (es) 2023-02-15
LT3532098T (lt) 2021-06-25
IL320372A (en) 2025-06-01
BR112019008244A2 (pt) 2019-07-16
EP3903821A1 (en) 2021-11-03
EP3532098B1 (en) 2021-04-07
KR20190075942A (ko) 2019-07-01
SG10202104036QA (en) 2021-05-28
CY1124648T1 (el) 2022-07-22
DK3532098T3 (da) 2021-05-25
SMT202100347T1 (it) 2021-07-12
MX2019004942A (es) 2019-08-12
CN109890418A (zh) 2019-06-14
CN118045175A (zh) 2024-05-17
KR102500868B1 (ko) 2023-02-16
IL301786B1 (en) 2025-05-01
PL3532098T3 (pl) 2022-01-31
KR20230028571A (ko) 2023-02-28

Similar Documents

Publication Publication Date Title
CN109890418B (zh) 抗cd19抗体与bcl-2抑制剂的组合及其用途
JP2023058502A (ja) 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用
US12194095B2 (en) Combinations and uses thereof
HK40064491A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40069168A (en) Combinations and uses thereof
HK40014532A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40014532B (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK1247122B (en) Combinations and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250311

Address after: Delaware, USA

Patentee after: INCYTE Corp.

Country or region after: U.S.A.

Address before: Praneger, Germany

Patentee before: MORPHOSYS AG

Country or region before: Germany